ADU 623Alternative Names: ADU-623
Latest Information Update: 04 May 2016
At a glance
- Originator Aduro BioTech
- Class Attenuated vaccines; Cancer vaccines; Synthetic vaccines
- Mechanism of Action Immunostimulants
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity No
Highest Development Phases
- Phase I Glioblastoma
Most Recent Events
- 04 May 2016 Phase I development in Glioblastoma is ongoing in the US
- 31 Oct 2013 Phase-I clinical trials in Glioblastoma (second-line therapy or greater) in USA (IV)